FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1892652546> ?p ?o ?g. }

• W1892652546 endingPage "2072" @default.
• W1892652546 startingPage "2066" @default.
• W1892652546 abstract "A previous randomized phase II study demonstrated that the addition of a c-Met inhibitor tivantinib to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib might prolong progression-free survival (PFS) in patients with previously treated, nonsquamous nonsmall-cell lung cancer (NSCLC). On a subset analysis, the survival benefit was greater in patients with wild-type EGFR (WT-EGFR) than in those with activating EGFR mutations. Herein, this phase III study compared overall survival (OS) between Asian nonsquamous NSCLC patients with WT-EGFR who received erlotinib plus tivantinib (tivantinib group) or erlotinib plus placebo (placebo group).A total of 460 NSCLC patients were planned to be randomized to the tivantinib or placebo group. Primary end point was OS. Secondary end points were PFS, tumor response, and safety. Tissue was collected for biomarker analysis, including c-Met and HGF expression.Enrollment was stopped when 307 patients were randomized, following the Safety Review Committee's recommendation based on an imbalance in the interstitial lung disease (ILD) incidence between the groups. ILD developed in 14 patients (3 deaths) and 6 patients (0 deaths) in the tivantinib and the placebo groups, respectively. In the enrolled patients, median OS was 12.7 and 11.1 months in the tivantinib and the placebo groups, respectively [hazard ratio (HR) = 0.891, P = 0.427]. Median PFS was 2.9 and 2.0 months in the tivantinib and the placebo groups, respectively (HR = 0.719, P = 0.019). The commonly observed grade ≥ 3 adverse events in the tivantinib group were neutropenia (24.3%), leukopenia (18.4%), febrile neutropenia (13.8%), and anemia (13.2%).This study was prematurely terminated due to the increased ILD incidence in the tivantinib group. Although this study lacked statistical power because of the premature termination and did not demonstrate an improvement in OS, our results suggest that tivantinib plus erlotinib might improve PFS than erlotinib alone in nonsquamous NSCLC patients with WT-EGFR.NCT01377376." @default.
• W1892652546 created "2016-06-24" @default.
• W1892652546 creator A5002202180 @default.
• W1892652546 creator A5004584143 @default.
• W1892652546 creator A5007143858 @default.
• W1892652546 creator A5008594172 @default.
• W1892652546 creator A5014756509 @default.
• W1892652546 creator A5015604127 @default.
• W1892652546 creator A5022022857 @default.
• W1892652546 creator A5024261346 @default.
• W1892652546 creator A5032337115 @default.
• W1892652546 creator A5034733511 @default.
• W1892652546 creator A5040117457 @default.
• W1892652546 creator A5050855780 @default.
• W1892652546 creator A5052287605 @default.
• W1892652546 creator A5052670273 @default.
• W1892652546 creator A5058150457 @default.
• W1892652546 creator A5078287634 @default.
• W1892652546 creator A5081110935 @default.
• W1892652546 date "2015-10-01" @default.
• W1892652546 modified "2023-09-29" @default.
• W1892652546 title "A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)" @default.
• W1892652546 cites W1970476748 @default.
• W1892652546 cites W1981664643 @default.
• W1892652546 cites W1981989535 @default.
• W1892652546 cites W1987709860 @default.
• W1892652546 cites W1995119153 @default.
• W1892652546 cites W2032425858 @default.
• W1892652546 cites W2046956238 @default.
• W1892652546 cites W2049937850 @default.
• W1892652546 cites W2051676630 @default.
• W1892652546 cites W2081263614 @default.
• W1892652546 cites W2095496928 @default.
• W1892652546 cites W2097026987 @default.
• W1892652546 cites W2116300649 @default.
• W1892652546 cites W2138297714 @default.
• W1892652546 cites W2140126391 @default.
• W1892652546 cites W2153477391 @default.
• W1892652546 cites W2165803850 @default.
• W1892652546 cites W3108750466 @default.
• W1892652546 doi "https://doi.org/10.1093/annonc/mdv288" @default.
• W1892652546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26153496" @default.
• W1892652546 hasPublicationYear "2015" @default.
• W1892652546 type Work @default.
• W1892652546 sameAs 1892652546 @default.
• W1892652546 citedByCount "101" @default.
• W1892652546 countsByYear W18926525462015 @default.
• W1892652546 countsByYear W18926525462016 @default.
• W1892652546 countsByYear W18926525462017 @default.
• W1892652546 countsByYear W18926525462018 @default.
• W1892652546 countsByYear W18926525462019 @default.
• W1892652546 countsByYear W18926525462020 @default.
• W1892652546 countsByYear W18926525462021 @default.
• W1892652546 countsByYear W18926525462022 @default.
• W1892652546 countsByYear W18926525462023 @default.
• W1892652546 crossrefType "journal-article" @default.
• W1892652546 hasAuthorship W1892652546A5002202180 @default.
• W1892652546 hasAuthorship W1892652546A5004584143 @default.
• W1892652546 hasAuthorship W1892652546A5007143858 @default.
• W1892652546 hasAuthorship W1892652546A5008594172 @default.
• W1892652546 hasAuthorship W1892652546A5014756509 @default.
• W1892652546 hasAuthorship W1892652546A5015604127 @default.
• W1892652546 hasAuthorship W1892652546A5022022857 @default.
• W1892652546 hasAuthorship W1892652546A5024261346 @default.
• W1892652546 hasAuthorship W1892652546A5032337115 @default.
• W1892652546 hasAuthorship W1892652546A5034733511 @default.
• W1892652546 hasAuthorship W1892652546A5040117457 @default.
• W1892652546 hasAuthorship W1892652546A5050855780 @default.
• W1892652546 hasAuthorship W1892652546A5052287605 @default.
• W1892652546 hasAuthorship W1892652546A5052670273 @default.
• W1892652546 hasAuthorship W1892652546A5058150457 @default.
• W1892652546 hasAuthorship W1892652546A5078287634 @default.
• W1892652546 hasAuthorship W1892652546A5081110935 @default.
• W1892652546 hasBestOaLocation W18926525461 @default.
• W1892652546 hasConcept C121608353 @default.
• W1892652546 hasConcept C126322002 @default.
• W1892652546 hasConcept C142724271 @default.
• W1892652546 hasConcept C143998085 @default.
• W1892652546 hasConcept C168563851 @default.
• W1892652546 hasConcept C197934379 @default.
• W1892652546 hasConcept C203092338 @default.
• W1892652546 hasConcept C204787440 @default.
• W1892652546 hasConcept C207103383 @default.
• W1892652546 hasConcept C27081682 @default.
• W1892652546 hasConcept C2776256026 @default.
• W1892652546 hasConcept C2778087573 @default.
• W1892652546 hasConcept C2779438470 @default.
• W1892652546 hasConcept C2909325608 @default.
• W1892652546 hasConcept C44249647 @default.
• W1892652546 hasConcept C71924100 @default.
• W1892652546 hasConcept C90924648 @default.
• W1892652546 hasConceptScore W1892652546C121608353 @default.
• W1892652546 hasConceptScore W1892652546C126322002 @default.
• W1892652546 hasConceptScore W1892652546C142724271 @default.
• W1892652546 hasConceptScore W1892652546C143998085 @default.
• W1892652546 hasConceptScore W1892652546C168563851 @default.
• W1892652546 hasConceptScore W1892652546C197934379 @default.
• W1892652546 hasConceptScore W1892652546C203092338 @default.

• next